AstraZeneca

FDA Approves TEZSPIRE® (tezepelumab-ekko) for Chronic Rhinosinusitis with Nasal Polyps, Expanding Its Use Beyond Severe Asthma

FDA Approves TEZSPIRE® (tezepelumab-ekko) for Chronic Rhinosinusitis with Nasal Polyps, Expanding Its Use Beyond Severe Asthma

18 Oct 2025

3 min read

AstraZeneca to Invest $50 Billion in US Expansion, Boost Access to Affordable Medicines

AstraZeneca to Invest $50 Billion in US Expansion, Boost Access to Affordable Medicines

11 Oct 2025

1 min read

AstraZeneca’s Baxdrostat Shows Significant Blood Pressure Reduction in Late-Stage Trial

AstraZeneca’s Baxdrostat Shows Significant Blood Pressure Reduction in Late-Stage Trial

08 Oct 2025

1 min read

Read More

Voice Of HealthCare

vohnetwork.com